4 days ago
LLY
AnalystsSrikripa DevarakondaSrikripa Devarakonda's Stock Forecasts
AnalystsSrikripa Devarakonda
Analyst Ranking
Top 9%
#475 out of 5550 analysts
Average Return
+18.85%
Win Rate
53%53 out of 100
Risk vs Reward
Poor
Good
Srikripa Devarakonda's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Terns Pharmaceuticals IncTERN | +520.24% | $8.50 | $52.72 | 2025-10-15 - 2026-03-31 | Strong Buy |
Mbx Biosciences IncMBX | +249.96% | $13.95 | $48.82 | 2025-10-15 - 2026-10-14 | Strong Buy |
Verastem IncVSTM | +229.72% | $2.49 | $8.21 | 2024-08-13 - 2025-08-12 | Strong Buy |
Terns Pharmaceuticals IncTERN | +202.47% | $17.43 | $52.72 | 2025-11-04 - 2026-03-31 | Strong Buy |
Edgewise Therapeutics IncEWTX | +131.48% | $7.56 | $17.50 | 2023-06-28 - 2024-06-27 | Strong Buy |
Srikripa Devarakonda Analyst Color
Get additional color on Srikripa Devarakonda's coverage of popular stocks
a month ago
IVA
a month ago
SRRK
a month ago
AXSM
2 months ago
SRRK
3 months ago
PTGX
3 months ago
MBX
3 months ago
CYTK
4 months ago
PTGX
4 months ago
SEPN
4 months ago
KYMR
6 months ago
MDGL
6 months ago
MBX
6 months ago
VTRS
7 months ago
PTGX
8 months ago
SEPN
8 months ago
SRRK
9 months ago
CYTK
10 months ago
PTGX
a year ago
KYMR
a year ago
KYMR
a year ago
MDGL
2 years ago
LLY
2 years ago
PFE
2 years ago
EWTX
Srikripa Devarakonda's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Kymera Therapeutics IncKYMR | 8 | Strong Buy | $150.00 | +17.64% | Reiterates | 4 days ago |
Eli Lilly & CoLLY | 5 | Strong Buy | $1,612.00 | +14.25% | Reiterates | 4 days ago |
Incyte CorpINCY | 14 | Hold | $115.00 | -4.20% | Maintains | 20 days ago |
Inventiva SaIVA | 2 | Strong Buy | $18.00 | +369.97% | Maintains | a month ago |
Scholar Rock Holding CorpSRRK | 8 | Strong Buy | $77.00 | +79.45% | Maintains | a month ago |
Axsome Therapeutics IncAXSM | 1 | Strong Buy | $285.00 | +109.54% | Maintains | a month ago |
Protagonist Therapeutics IncPTGX | 7 | Strong Buy | $170.00 | +21.98% | Maintains | 3 months ago |
Mbx Biosciences IncMBX | 3 | Strong Buy | $88.00 | +61.76% | Maintains | 3 months ago |
Cytokinetics IncCYTK | 6 | Strong Buy | $112.00 | +80.56% | Maintains | 3 months ago |
Absci CorpABSI | 2 | Strong Buy | $17.00 | +75.44% | Maintains | 4 months ago |
Septerna IncSEPN | 3 | Strong Buy | $43.00 | -0.46% | Maintains | 4 months ago |
Madrigal Pharmaceuticals IncMDGL | 3 | Strong Buy | $709.00 | +64.44% | Maintains | 6 months ago |
Viatris IncVTRS | 2 | Strong Buy | $20.00 | +7.12% | Maintains | 6 months ago |
Biogen IncBIIB | 7 | Hold | $189.00 | -24.10% | Maintains | 7 months ago |
Terns Pharmaceuticals IncTERN | 5 | Hold | $53.00 | +0.09% | Downgrades | 7 months ago |
Regeneron Pharmaceuticals IncREGN | 8 | Strong Buy | $812.00 | N/A | Maintains | a year ago |
Arvinas IncARVN | 1 | Hold | $11.00 | N/A | Downgrades | a year ago |
Keros Therapeutics IncKROS | 5 | Strong Buy | $25.00 | N/A | Maintains | 2 years ago |
Abbvie IncABBV | 3 | Strong Buy | $217.00 | N/A | Maintains | 2 years ago |
Pfizer IncPFE | 1 | Strong Buy | $32.00 | N/A | Maintains | 2 years ago |
Edgewise Therapeutics IncEWTX | 6 | Strong Buy | $50.00 | N/A | Maintains | 2 years ago |
Biomea Fusion IncBMEA | 1 | Strong Buy | $54.00 | N/A | Upgrades | 2 years ago |
Verastem IncVSTM | 7 | Strong Buy | $15.00 | N/A | Maintains | 2 years ago |
Nurix Therapeutics IncNRIX | 1 | Strong Buy | $36.00 | N/A | Initiates Coverage On | 2 years ago |
Affimed NvAFMDQ | 2 | Strong Buy | $60.00 | N/A | Maintains | 3 years ago |
9 Meters Biopharma IncNMTRQ | 3 | Hold | $38.00 | N/A | Downgrades | 4 years ago |
Constellation Pharmaceuticals IncCNST | 2 | Hold | $34.00 | N/A | Downgrades | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.